Antisense Therapeutics Limited
ATHJF · OTC
6/30/2024 | 12/30/2023 | 6/30/2023 | 12/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.05 | -0.11 | -0.04 |
| FCF Yield | -28.69% | -18.36% | -11.18% | -4.04% |
| EV / EBITDA | -0.96 | -1.94 | -6.45 | -8.97 |
| Quality | ||||
| ROIC | -75.82% | -28.77% | -64.18% | -32.44% |
| Gross Margin | 98.92% | 96.41% | 98.73% | 96.10% |
| Cash Conversion Ratio | 0.75 | 1.02 | 0.92 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | 80.87% | 81.81% | 65.90% | 41.47% |
| Free Cash Flow Growth | -10.86% | 13.74% | -118.53% | 39.19% |
| Safety | ||||
| Net Debt / EBITDA | 1.65 | 3.63 | 1.77 | 3.12 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -17,522.78 | -1,047.63 | -6,524.48 | -4,151.59 |